Say Goodbye to Free COVID-19 Shots: CDC Approves Priced Boosters for Omicron Subvariants
Portfolio Pulse from Vandana Singh
The CDC has endorsed COVID-19 booster shots for individuals six months and older, with updated boosters from Pfizer Inc and Moderna Inc cleared by the FDA. The boosters target the Omicron subvariant XBB.1.5 and have shown strong immune responses. This is the first season where COVID-19 shots are not universally free, with Moderna setting a list price of $129 per dose and Pfizer's list price at $115 per dose. PFE shares are up 0.26% at $34.24 and MRNA shares are trading higher by 4.14% at $109.60.
September 13, 2023 | 11:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's updated COVID-19 booster has been endorsed by the CDC and cleared by the FDA. The company has set a list price of $129 per dose. MRNA shares are trading higher by 4.14%.
The endorsement and clearance of Moderna's updated booster by the CDC and FDA respectively, coupled with the set price for the booster, are likely to increase the company's revenues and thus positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer's updated COVID-19 booster has been endorsed by the CDC and cleared by the FDA. The company has set a list price of $115 per dose. PFE shares are up 0.26%.
The endorsement and clearance of Pfizer's updated booster by the CDC and FDA respectively, coupled with the set price for the booster, are likely to increase the company's revenues and thus positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100